Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
|Videos|June 18, 2015
Hepatitis C: Short Term Drug Costs Versus Long Term Care Costs
Author(s)Davy James, Managing Editor
Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.
Advertisement
Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.
This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
2
Understanding Kratom: Pharmacology, Safety, and Regulation
3
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5